Menu
Dirk Nagorsen, MD, is the Chief Medical Officer of Affini-T Therapeutics. He has more than 20 years of experience in hematology and oncology, both in academia and industry. Previously he was Vice President Early Development and Therapeutic Area Head, Hematology & Oncology Early Development at Amgen, where he oversaw more than 30 oncology programs spanning IND filings through drug approvals, most notably Lumakras®, the first approved KRAS inhibitor. He also served as the Global Development Leader for blinatumomab/Blincyto®, a CD3 bispecific T cell engager targeting CD19, and led his team to secure Amgen’s first breakthrough designation and first accelerated approval in 2014. Before joining Amgen, he served as a Senior Medical Director at Micromet, a German biotech, through its acquisition by Amgen in 2012. Dirk’s groundbreaking research has resulted in over 60 peer-reviewed manuscripts, including papers published in New England Journal of Medicine, Journal of Clinical Oncology and Lancet Oncology.
Dirk earned his medical doctorate and his habilitation (second scientific degree, equivalent of a PhD) in experimental medicine and tumor immunology from Charité University Medicine Berlin. He trained in internal medicine, hematology,and oncology at the Free University Berlin Medical School, at the NIH Clinical Center Bethesda, Maryland, and at Charité University Medicine Berlin.
Dirk Nagorsen, MD, is the Chief Medical Officer of Affini-T Therapeutics. He has more than 20 years of experience in hematology and oncology, both in academia and industry. Previously he was Vice President Early Development and Therapeutic Area Head, Hematology & Oncology Early Development at Amgen, where he oversaw more than 30 oncology programs spanning IND filings through drug approvals, most notably Lumakras®, the first approved KRAS inhibitor. He also served as the Global Development Leader for blinatumomab/Blincyto®, a CD3 bispecific T cell engager targeting CD19, and led his team to secure Amgen’s first breakthrough designation and first accelerated approval in 2014. Before joining Amgen, he served as a Senior Medical Director at Micromet, a German biotech, through its acquisition by Amgen in 2012. Dirk’s groundbreaking research has resulted in over 60 peer-reviewed manuscripts, including papers published in New England Journal of Medicine, Journal of Clinical Oncology and Lancet Oncology.
Dirk earned his medical doctorate and his habilitation (second scientific degree, equivalent of a PhD) in experimental medicine and tumor immunology from Charité University Medicine Berlin. He trained in internal medicine, hematology,and oncology at the Free University Berlin Medical School, at the NIH Clinical Center Bethesda, Maryland, and at Charité University Medicine Berlin.
Lorem ipsum dolor sit amet, consetetur sadi atpscing elitr, sed diam nonumy eirmod tempor eos invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eta loeos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor si amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo ea rebum. Lorem ipsum dolor sit amet, consetetur sadi atpscing elitr, sed diam nonumy eirmod tempor eos invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eta loeos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor si amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo ea rebum. Lorem ipsum dolor si amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo ea rebum. Lorem ipsum dolor sit amet, consetetur sadi atpscing elitr, sed diam nonumy eirmod tempor eos invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eta loeos et
